Patents by Inventor Mariano A. Garcia-Blanco

Mariano A. Garcia-Blanco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250127870
    Abstract: One solution to the problem of Hantavirus pathology is design, production, and administration of a nucleic acid vaccine (NAV). In certain aspect the NAV is an mRNA vaccine. Certain embodiments are directed to the use of a polyprotein, which is cleaved to produce Gn (N-terminal) and Gc (C-terminal) glycoproteins, the Gn glycoprotein, the Gc glycoprotein, or the Gn and Gc glycoproteins hantaviruses as protective antigen(s) for development of hantavirus vaccines. The Gn/Gc protein, which is cleaved post-translationally to individual Gn and Gc proteins, can be used as an antigen for vaccines. In case of DNA and RNA-based vaccines, the complete M gene, which encodes the complete single open reading frame, which is cleaved post-translationally in the Gn and Gc proteins or individual open reading frames encoding either Gn or Gc, is used.
    Type: Application
    Filed: September 15, 2022
    Publication date: April 24, 2025
    Inventors: Alexander Bukreyev, Mariano Garcia-Blanco, Ivan Kuzmin, Ruben Soto Acosta
  • Patent number: 12247206
    Abstract: The present invention includes compositions and methods for treating an autoimmune disorder or a cancer in a subject in need thereof, the method comprising: administering an effective amount of a composition comprising an oligonucleotide that specifically binds a complementary sequence of the Interleukin-7 receptor (IL7R) pre-mRNA that influences splicing of exon 6, wherein the SM-ASO increases or decreases inclusion of exon 6 in IL7R pre-mRNAs and respectively decreases or increases expression of the soluble isoform of IL7R (sIL7R). In certain embodiments, the oligonucleotide is an antisense oligonucleotide (ASO), or a splice-modulating antisense oligonucleotide (SM-ASO).
    Type: Grant
    Filed: October 16, 2023
    Date of Patent: March 11, 2025
    Assignee: Board of Regents, The University of Texas System
    Inventors: Mariano A. Garcia-Blanco, Gaddiel Galarza-Munoz, Shelton S. Bradrick
  • Patent number: 12203138
    Abstract: The present invention includes a method, kits, and assays for identifying a human subject as having an increased risk of developing an autoimmune disease, or a human subject with multiple sclerosis caused by elevated soluble Interleukin 7 receptor (sIL7R), by obtaining a biological sample and detecting or measuring in the biological sample an amount of a soluble Interleukin-7 receptor (sIL7R) and an amount of an RNA Helicase DDX39B, whereby a lower expression of DDX39B and a higher secretion of sIL7R identifies the subject from which the biological sample was obtained as having an increased risk of developing an autoimmune disease, when compared to a human subject not having an autoimmune disease. The present invention also includes a method of modifying a treating of subjects based on the lower expression of RNA Helicase DDX39B alone or in combination with an increase in sIL7R.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: January 21, 2025
    Assignees: Board of Regents, The University of Texas System, Duke University, Case Western Reserve, The Regents of the University of California
    Inventors: Mariano A. Garcia-Blanco, Gaddiel Galarza-Munoz, Simon G. Gregory, Farren B. S. Briggs, Lisa F. Barcellos, Shelton S. Bradrick, Irina Evsyukova, Dennis C. Ko
  • Publication number: 20240093203
    Abstract: The present invention includes compositions and methods for treating an autoimmune disorder or a cancer in a subject in need thereof, the method comprising: administering an effective amount of a composition comprising an oligonucleotide that specifically binds a complementary sequence of the Interleukin-7 receptor (IL7R) pre-mRNA that influences splicing of exon 6, wherein the SM-ASO increases or decreases inclusion of exon 6 in IL7R pre-mRNAs and respectively decreases or increases expression of the soluble isoform of IL7R (sIL7R). In certain embodiments, the oligonucleotide is an antisense oligonucleotide (ASO), or a splice-modulating antisense oligonucleotide (SM-ASO).
    Type: Application
    Filed: October 16, 2023
    Publication date: March 21, 2024
    Inventors: Mariano A. Garcia-Blanco, Gaddiel Galarza-Munoz, Shelton S. Bradrick
  • Publication number: 20240093204
    Abstract: The present invention includes compositions and methods for treating an autoimmune disorder or a cancer in a subject in need thereof, the method comprising: administering an effective amount of a composition comprising an oligonucleotide that specifically binds a complementary sequence of the Interleukin-7 receptor (IL7R) pre-mRNA that influences splicing of exon 6, wherein the SM-ASO increases or decreases inclusion of exon 6 in IL7R pre-mRNAs and respectively decreases or increases expression of the soluble isoform of IL7R (sIL7R). In certain embodiments, the oligonucleotide is an antisense oligonucleotide (ASO), or a splice-modulating antisense oligonucleotide (SM-ASO).
    Type: Application
    Filed: November 6, 2023
    Publication date: March 21, 2024
    Applicant: Board of Regents, The University of Texas System
    Inventors: Mariano A. Garcia-Blanco, Gaddiel Galarza-Munoz, Shelton S. Bradrick
  • Patent number: 11807853
    Abstract: The present invention includes compositions and methods for treating an autoimmune disorder or a cancer in a subject in need thereof, the method comprising: administering an effective amount of a composition comprising an oligonucleotide that specifically binds a complementary sequence of the Interleukin-7 receptor (IL7R) pre-mRNA that influences splicing of exon 6, wherein the SM-ASO increases or decreases inclusion of exon 6 in IL7R pre-mRNAs and respectively decreases or increases expression of the soluble isoform of IL7R (sIL7R). In certain embodiments, the oligonucleotide is an antisense oligonucleotide (ASO), or a splice-modulating antisense oligonucleotide (SM-ASO).
    Type: Grant
    Filed: August 25, 2021
    Date of Patent: November 7, 2023
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Mariano A. Garcia-Blanco, Gaddiel Galarza-Munoz, Shelton S. Bradrick
  • Publication number: 20230184776
    Abstract: Provided are methods for detecting or isolating circulating tumor cells (CTCs) in a subject. The methods may include detecting the expression of at least one epithelial mesenchymal transition (EMT) biomarker. Further provided are kits for detecting or isolating CTCs. The kits may include antibodies to at least one EMT biomarker. Further provided are methods of predicting the responsiveness of a subject to a cancer drug, methods of targeting delivery of a cancer drug in a subject, methods of providing a cancer prognosis to a subject, and methods for following the progress of cancer in a subject.
    Type: Application
    Filed: December 8, 2022
    Publication date: June 15, 2023
    Inventors: Galla Chandra Rao, Mark C. Connelly, Mariano A. Garcia-Blanco, Andrew J. Armstrong, Rhonda L. Bitting
  • Patent number: 11567081
    Abstract: Provided are methods for detecting or isolating circulating tumor cells (CTCs) in a subject. The methods may include detecting the expression of at least one epithelial mesenchymal transition (EMT) biomarker. Further provided are kits for detecting or isolating CTCs. The kits may include antibodies to at least one EMT biomarker. Further provided are methods of predicting the responsiveness of a subject to a cancer drug, methods of targeting delivery of a cancer drug in a subject, methods of providing a cancer prognosis to a subject, and methods for following the progress of cancer in a subject.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: January 31, 2023
    Assignees: Duke University, Menarini Silicon Biosystems S.p.A.
    Inventors: Galla Chandra Rao, Mark C. Connelly, Mariano A. Garcia-Blanco, Andrew J. Armstrong, Rhonda L. Bitting
  • Publication number: 20210403920
    Abstract: The present invention includes compositions and methods for treating an autoimmune disorder or a cancer in a subject in need thereof, the method comprising: administering an effective amount of a composition comprising an oligonucleotide that specifically binds a complementary sequence of the Interleukin-7 receptor (IL7R) pre-mRNA that influences splicing of exon 6, wherein the SM-ASO increases or decreases inclusion of exon 6 in IL7R pre-mRNAs and respectively decreases or increases expression of the soluble isoform of IL7R (sIL7R). In certain embodiments, the oligonucleotide is an antisense oligonucleotide (ASO), or a splice-modulating antisense oligonucleotide (SM-ASO).
    Type: Application
    Filed: August 25, 2021
    Publication date: December 30, 2021
    Inventors: Mariano A. Garcia-Blanco, Gaddiel Galarza-Munoz, Shelton S. Bradrick
  • Patent number: 11118186
    Abstract: The present invention includes compositions and methods for treating an autoimmune disorder or a cancer in a subject in need thereof, the method comprising: administering an effective amount of a composition comprising an oligonucleotide that specifically binds a complementary sequence of the Interleukin-7 receptor (IL7R) pre-mRNA that influences splicing of exon 6, wherein the SM-ASO increases or decreases inclusion of exon 6 in IL7R pre-mRNAs and respectively decreases or increases expression of the soluble isoform of IL7R (sIL7R). In certain embodiments, the oligonucleotide is an antisense oligonucleotide (ASO), or a splice-modulating antisense oligonucleotide (SM-ASO).
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: September 14, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Mariano A. Garcia-Blanco, Gaddiel Galarza-Munoz, Shelton S. Bradrick
  • Publication number: 20210180133
    Abstract: The present invention includes a method, kits, and assays for identifying a human subject as having an increased risk of developing an autoimmune disease, or a human subject with multiple sclerosis caused by elevated soluble Interleukin 7 receptor (sIL7R), by obtaining a biological sample and detecting or measuring in the biological sample an amount of a soluble Interleukin-7 receptor (sIL7R) and an amount of an RNA Helicase DDX39B, whereby a lower expression of DDX39B and a higher secretion of sIL7R identifies the subject from which the biological sample was obtained as having an increased risk of developing an autoimmune disease, when compared to a human subject not having an autoimmune disease. The present invention also includes a method of modifying a treating of subjects based on the lower expression of RNA Helicase DDX39B alone or in combination with an increase in sIL7R.
    Type: Application
    Filed: February 23, 2021
    Publication date: June 17, 2021
    Applicants: Board of Regents, The University of Texas System, Duke University, Case Western Reserve University, University of California, Berkeley
    Inventors: Mariano A. Garcia-Blanco, Gaddiel Galarza-Munoz, Simon G. Gregory, Farren B. S. Briggs, Lisa F. Barcellos, Shelton S. Bradrick, Irina Evsyukova, Dennis C. Ko
  • Patent number: 10961581
    Abstract: The present invention includes a method, kits, and assays for identifying a human subject as having an increased risk of developing an autoimmune disease, or a human subject with multiple sclerosis caused by elevated soluble Interleukin 7 receptor (sIL7R), by obtaining a biological sample and detecting or measuring in the biological sample an amount of a soluble Interleukin-7 receptor (sIL7R) and an amount of an RNA Helicase DDX39B, whereby a lower expression of DDX39B and a higher secretion of sIL7R identifies the subject from which the biological sample was obtained as having an increased risk of developing an autoimmune disease, when compared to a human subject not having an autoimmune disease. The present invention also includes a method of modifying a treating of subjects based on the lower expression of RNA Helicase DDX39B alone or in combination with an increase in sIL7R.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: March 30, 2021
    Assignees: Board of Regents, The University of Texas System, Duke University, Case Western Reserve, The Regents of the University of California
    Inventors: Mariano A. Garcia-Blanco, Gaddiel Galarza-Munoz, Simon G. Gregory, Farren B. S. Briggs, Lisa F. Barcellos, Shelton S. Bradrick, Irina Evsyukova, Dennis C. Ko
  • Publication number: 20210024938
    Abstract: The present invention includes compositions and methods for treating an autoimmune disorder or a cancer in a subject in need thereof, the method comprising: administering an effective amount of a composition comprising an oligonucleotide that specifically binds a complementary sequence of the Interleukin-7 receptor (IL7R) pre-mRNA that influences splicing of exon 6, wherein the SM-ASO increases or decreases inclusion of exon 6 in IL7R pre-mRNAs and respectively decreases or increases expression of the soluble isoform of IL7R (sIL7R). In certain embodiments, the oligonucleotide is an antisense oligonucleotide (ASO), or a splice-modulating antisense oligonucleotide (SM-ASO).
    Type: Application
    Filed: September 21, 2020
    Publication date: January 28, 2021
    Applicant: Board of Regents, The University of Texas System
    Inventors: Mariano A. Garcia-Blanco, Gaddiel Galarza-Munoz, Shelton S. Bradrick
  • Publication number: 20190107542
    Abstract: Provided are methods for detecting or isolating circulating tumor cells (CTCs) in a subject. The methods may include detecting the expression of at least one epithelial mesenchymal transition (EMT) biomarker. Further provided are kits for detecting or isolating CTCs. The kits may include antibodies to at least one EMT biomarker. Further provided are methods of predicting the responsiveness of a subject to a cancer drug, methods of targeting delivery of a cancer drug in a subject, methods of providing a cancer prognosis to a subject, and methods for following the progress of cancer in a subject.
    Type: Application
    Filed: November 30, 2018
    Publication date: April 11, 2019
    Inventors: Galla Chandra Rao, Mark C. Connelly, Mariano A. Garcia-Blanco, Andrew J. Armstrong, Rhonda L. Bitting
  • Patent number: 10161939
    Abstract: Provided are methods for detecting or isolating circulating tumor cells (CTCs) in a subject. The methods may include detecting the expression of at least one epithelial mesenchymal transition (EMT) biomarker. Further provided are kits for detecting or isolating CTCs. The kits may include antibodies to at least one EMT biomarker. Further provided are methods of predicting the responsiveness of a subject to a cancer drug, methods of targeting delivery of a cancer drug in a subject, methods of providing a cancer prognosis to a subject, and methods for following the progress of cancer in a subject.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: December 25, 2018
    Assignees: Duke University, Janssen Diagnostics, LLC
    Inventors: Galla Chandra Rao, Mark C. Connelly, Mariano A. Garcia-Blanco, Andrew J. Armstrong, Rhonda L. Bitting
  • Publication number: 20180274033
    Abstract: The present invention includes a method, kits, and assays for identifying a human subject as having an increased risk of developing an autoimmune disease, or a human subject with multiple sclerosis caused by elevated soluble Interleukin 7 receptor (sIL7R), by obtaining a biological sample and detecting or measuring in the biological sample an amount of a soluble Interleukin-7 receptor (sIL7R) and an amount of an RNA Helicase DDX39B, whereby a lower expression of DDX39B and a higher secretion of sIL7R identifies the subject from which the biological sample was obtained as having an increased risk of developing an autoimmune disease, when compared to a human subject not having an autoimmune disease. The present invention also includes a method of modifying a treating of subjects based on the lower expression of RNA Helicase DDX39B alone or in combination with an increase in sIL7R.
    Type: Application
    Filed: March 22, 2018
    Publication date: September 27, 2018
    Applicants: Board of Regents, The University of Texas System, Duke University, Case Western Reserve University, University Of California, Berkeley
    Inventors: Mariano A. Garcia-Blanco, Gaddiel Galarza-Munoz, Simon G. Gregory, Farren B.S. Briggs, Lisa F. Barcellos, Shelton S. Bradrick, Irina Evsyukova, Dennis C. Ko
  • Publication number: 20180231560
    Abstract: This disclosure provides compositions and methods for the isolation of cells that express c-MET, and in particular circulating tumor cells that express c-MET. The methods can include contacting a biological sample including a c-MET circulating tumor cell with an unbound complex including a capture binding species linked to a solid phase for a time sufficient to allow the unbound complex to bind an extracellular binding domain of the c-MET protein to form a bound complex, and subsequently isolating the bound complex. Compositions, systems, and kits adapted for use with these methods are also provided.
    Type: Application
    Filed: September 15, 2015
    Publication date: August 16, 2018
    Inventors: Galla Chandra Rao, Mark C. Connelly, Rengasamy BOOMINATHAN, Tian Zhang, Mariano A. Garcia-Blanco, Andrew J. Armstrong
  • Patent number: 9845481
    Abstract: Synthetic regulation of gene expression is provided. In some embodiments, synthetic regulatory constructs are provided. In some embodiments, a synthetic regulatory construct expresses a heterologous gene in a selected cell type. In some embodiments, methods of expressing a heterologous gene in a selected cell type are provided.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: December 19, 2017
    Assignee: Duke University
    Inventors: Matthew S. Marengo, Mariano A. Garcia-Blanco
  • Publication number: 20160281107
    Abstract: Synthetic regulation of gene expression is provided. In some embodiments, synthetic regulatory constructs are provided. In some embodiments, a synthetic regulatory construct expresses a heterologous gene in a selected cell type. In some embodiments, methods of expressing a heterologous gene in a selected cell type are provided.
    Type: Application
    Filed: February 29, 2016
    Publication date: September 29, 2016
    Applicant: Duke University
    Inventors: Matthew S. Marengo, Mariano A. Garcia-Blanco
  • Publication number: 20160077097
    Abstract: Provided are methods for detecting or isolating circulating tumor cells (CTCs) in a subject. The methods may include detecting the expression of at least one epithelial mesenchymal transition (EMT) biomarker. Further provided are kits for detecting or isolating CTCs. The kits may include antibodies to at least one EMT biomarker. Further provided are methods of predicting the responsiveness of a subject to a cancer drug, methods of targeting delivery of a cancer drug in a subject, methods of providing a cancer prognosis to a subject, and methods for following the progress of cancer in a subject.
    Type: Application
    Filed: May 31, 2013
    Publication date: March 17, 2016
    Inventors: Galla Chandra Rao, Mark C. Connelly, Mariano A. Garcia-Blanco, Andrew J. Armstrong, Rhonda L. Bitting